The inhibition of PARP-1 activation by PARP-1 gene depletion or pharmacological inhibitors can prevent OL damage and myelin depletion in mouse models of periventricular leukomalacia [49]. The gene discussed is PARP1; the disease is periventricular leukomalacia.